Rutger Daems, PhD, Edith Maes, DBA, Christoph Glaetzer, Dipl, Kfm 

Slides:



Advertisements
Similar presentations
Performance Assessment of the Juaboso District Office of the National Health Insurance Authority  Paul Effah, MBA, Kingsley Opoku Appiah, PhD, FCCA, Patience.
Advertisements

Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Volume 15, Issue 2, Pages (March 2012)
Examining the Value of Menopausal Symptom Relief Among US Women
Value and Service Quality Assessment of the National Health Insurance Scheme in Ghana: Evidence from Ashiedu Keteke District  Eric Nsiah-Boateng, MSc,
Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico  Kely Rely, Rosa María.
Value in Health Regional Issues
Value in Health Regional Issues
Eric Nsiah-Boateng, MPH, Moses Aikins, PhD 
Value and Service Quality Assessment of the National Health Insurance Scheme in Ghana: Evidence from Ashiedu Keteke District  Eric Nsiah-Boateng, MSc,
Value in Health Regional Issues
The Development of the Romanian Scorecard HTA System
Using Dynamic Transmission Modeling to Determine Vaccination Coverage Rate Based on 5-Year Economic Burden of Infectious Disease: An Example of Pneumococcal.
Value in Health Regional Issues
Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt
From Regulatory Approval to Subsidized Patient Access in the Asia-Pacific Region: A Comparison of Systems Across Australia, China, Japan, Korea, New Zealand,
Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future?  Emmanuel Ankrah Odame, MBCHB, MPH  Value in.
The Cost-Effectiveness Analysis of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) for Females in Japan  Kaoru Yamabe, MSc, Puneet K. Singhal,
Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam: Application of Cost- Effectiveness Affordability Curves in Health Care Decision Making 
Prevalence, Awareness, Treatment, and Burden of Major Depressive Disorder: Estimates from the National Health and Wellness Survey in Brazil  Ronaldo K.
Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico  Kely Rely, Rosa María.
Value in Health Regional Issues
Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs)
The Process of Privatization of Health Care Provision in Poland
Boxiong Tang, MD, PhD, Eran Harary, MD, Ricky Kurzman, MSc, Joaquín F
Ernest Attuquaye Quaye, BPharm, MPH, Edward O
The Living with Medicines Questionnaire: Translation and Cultural Adaptation into the Arabic Context  Amani Zidan, BScPharm, Ahmed Awaisu, PhD, Sanah.
Value in Health Regional Issues
Capacity Building for HTA Implementation in Middle-Income Countries: The Case of Hungary  Zoltán Kaló, MSc, MD, PhD, József Bodrogi, MSc, Imre Boncz,
Cost-Effectiveness Analysis of a Screening Program for Breast Cancer in Vietnam  Lan Hoang Nguyen, Wongsa Laohasiriwong, John Frederick Stewart, Pamela.
Cost-Benefit Analysis and Assessment of Quality of Care in patients with Hemophilia undergoing treatment at National Rural Health Mission in Maharashtra,
Value in Health Regional Issues
Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore  Vivianne Shih, PharmD, BCOP, BCPS, Alexandre Chan, PharmD,
What Is Important During the Selection of Traditional Chinese Medicine (TCM) in a Health Care Reimbursement or Insurance System?” Critical Issues of Assessment.
Assessment of Adverse Events and Quality of Life of Cancer Patients in a Secondary Level Care, Rural Hospital in South India  S.K.R. Sowmya, PharmD, Dixon.
Assessment of Effect of Diabetes on Health-Related Quality of Life in Patients with Coronary Artery Disease Using the EQ-5D Questionnaire  Bhavik Shah,
Jinhyun Kim, PhD, Eunhee Lee, PhD, Sungjae Kim, PhD, Tae Jin Lee, PhD 
Bernadette A. Tumanan-Mendoza, MD, MScE, MHE, Victor L. Mendoza, MD 
Omneya Mohamed, PhD, David H. Kreling, PhD 
Patient Utility Measurement for Managing Ureteral Stones: A Modified Standard Gamble Approach  Ching-Yuan Fann, PhD, Po-Chien Huang, MD, MS, Amy Ming-Fang.
Value in Health Regional Issues
The Economic Impact of Cigarette Smoking on the Poor in Jordan
Burden of Disease Studies in the Asia-Pacific Region: Are There Enough being Performed to Provide Information for Evidence-Based Health Policy?  Fei-Li.
A Framework for Applying Health Technology Assessment in Cyprus: Thoughts, Success Stories, and Recommendations  Panagiotis Petrou, MBA, PhD, PhDc, Michalis.
Transforming Public Servants’ Health Care Organization in Greece through the Implementation of an Electronic Referral Project  Kyriakos Souliotis, PhD,
Cost-Effectiveness of Biologic Agents in the Treatment of Moderate-to-Severe Psoriasis: A Brazilian Public Health Service Perspective  Bruno Salgado Riveros,
Generalized Cost-Effectiveness Analysis of Pharmaceutical Interventions for Primary Prevention of Cardiovascular Disease in Thailand  Panrasri Khonputsa,
Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes  Maxwell O. Adibe,
Cost-Effectiveness Analysis Expands its Reach Worldwide
Reconciling Cancer Care Costs Reported by Different Government Agencies in Taiwan: Why Costing Approach Matters?  Chun-Ru Chien, MD, PhD, Ya-Chen Tina.
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Incidence of Intravenous Medication Errors in a Chinese Hospital
Use of the EQ-5D Instrument and Value Scale in Comparing Health States of Patients in Four Health Care Programs among Health Care Providers  Valentina.
Pei Wang, PhD, Nan Luo, PhD, E.S. Tai, PhD, Julian Thumboo, PhD 
Guidance Document: Global Pharmacoeconomic Model Adaption Strategies
Value in Health Regional Issues
Value in Health Regional Issues
Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea  Ji Haeng Heo, MS, Karen L.
Dossier System as a Practical Tool for Compiling Reimbursement Lists
Concept of Combining Cost-Effectiveness Analysis and Budget Impact Analysis in Health Care Decision-Making  Roza Ismailovna Yagudina, PhD, Andrey Urievich.
Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico 
Performance Assessment of the Juaboso District Office of the National Health Insurance Authority  Paul Effah, MBA, Kingsley Opoku Appiah, PhD, FCCA, Patience.
The Drug Reimbursement Decision-Making System in Iran
Social Cost of Substance Abuse in Russia
Anut Sakulsupsiri, MSc, Phantipa Sakthong, PhD, Win Winit-Watjana, PhD 
Clinical Burden of Invasive Pneumococcal Disease in Selected Developing Countries  Namaitijiang Maimaiti, PhD, Zafar Ahmed, PhD, Zaleha Md Isa, PhD, Hasanain.
Victoria I. Ignatyeva, MPH, Johan L
Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Asthma in Japan and the Value of Responder Prediction Methods Based on a Multinational.
Evaluation of Quality of Pharmacoeconomic Studies in Asia-Pacific Region and Identification of Influencing Variables  Prabhakar Pandey, MPharm, Rishabh.
Abdol Majid Cheraghali, PhD, Peyman Eshghi, MD 
Presentation transcript:

Equity in Pharmaceutical Pricing and Reimbursement: Crossing the Income Divide in Asia Pacific  Rutger Daems, PhD, Edith Maes, DBA, Christoph Glaetzer, Dipl, Kfm  Value in Health Regional Issues  Volume 2, Issue 1, Pages 160-166 (May 2013) DOI: 10.1016/j.vhri.2013.03.001 Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 1 International pricing policy framework and process. ATP, ability to pay; CEA, cost-effectiveness analysis; WTP, willingness to pay. Value in Health Regional Issues 2013 2, 160-166DOI: (10.1016/j.vhri.2013.03.001) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 2 Cost-effectiveness and policy decisions. ICER, incremental cost-effectiveness ratio. Value in Health Regional Issues 2013 2, 160-166DOI: (10.1016/j.vhri.2013.03.001) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 3 Pricing using HDI- and GNI-based indexes. GNI, gross national income; HDI, human development index; PPP, purchasing power parity. Value in Health Regional Issues 2013 2, 160-166DOI: (10.1016/j.vhri.2013.03.001) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 4 Trend of equitable discounts in period 2010-2050 (selection of countries). Value in Health Regional Issues 2013 2, 160-166DOI: (10.1016/j.vhri.2013.03.001) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 5 ATP method applied to a globally marketed medicine. ATP, ability to pay; GNI, gross national income; PPP, purchasing power parity. Value in Health Regional Issues 2013 2, 160-166DOI: (10.1016/j.vhri.2013.03.001) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 6 ATP index per country versus equitable pricing standard. ATP, ability to pay. Value in Health Regional Issues 2013 2, 160-166DOI: (10.1016/j.vhri.2013.03.001) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.